JPMorgan analyst Jessica Fye lowered the firm’s price target on BioMarin (BMRN) to $109 from $110 and keeps an Overweight rating on the shares post the Q3 report. The firm sees an attractive entry point at current share levels, citing BioMarin’s “durable base business and potential for meaningful operating margin expansion over the next few years.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BMRN:
- William Blair downgrades BioMarin to Market Perform on lack of catalysts
- BioMarin downgraded to Market Perform from Outperform at William Blair
- BioMarin Reports Strong Q3 Growth and Positive Outlook
- BioMarin raises FY24 non-GAAP EPS view to $3.25-$3.35 from $3.10-$3.25
- BioMarin reports Q3 non-GAAP EPS 91c, consensus 52c
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
